Medicine should be more like Missouri

Circulation: Cardiovascular Quality and Outcomes

Volumn 2, Issue 4, 2009, Pages 289-291

  Krumholz, Harlan M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TORCETRAPIB;

ACUTE HEART INFARCTION; CARDIOVASCULAR SURGERY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; INFORMATION DISSEMINATION; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; MEDICAL RESEARCH; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURVIVAL RATE; THERAPY DELAY; UNITED STATES; CARDIOLOGY; STANDARD;

CARDIOLOGY; DELIVERY OF HEALTH CARE; HUMANS; MISSOURI; QUALITY OF HEALTH CARE;

EID: 77949883412     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.109.886010     Document Type: Editorial

References (17)

1. Missouri Secretary of State. Missouri history: why is Missouri called the "Show-Me" State? http://www.sos.mo.gov/archives/history/slogan.asp. Accessed June 9, 2009.
2. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of β-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA. 1998;280:623-629.
3. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, Wang Y, Jencks SF. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med. 1996;124:292-298.
4. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, Wang Y, Kresowik TF, Jencks SF. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries: patterns of use and outcomes. Circulation. 1995;92:2841-2847.
5. Krumholz HM, Vaccarino V, Ellerbeck EF, Kiefe C, Hennen J, Kresowik TF, Gold JA, Jencks SF, Radford MJ. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons > or = 65 years of age. Am J Cardiol. 1997;79: 581-586.
6. Jha AK, Li Z, Orav EJ, Epstein AM. Care in U.S. hospitals: the Hospital Quality Alliance program. N Engl J Med. 2005;353:265-274.
7. Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Canada. N Engl J Med. 2008;358: 1819-1828.
8. ClinicalTrials.gov. IMPROVE-IT: Examining outcomes in subjects with acute coronary syndrome: vytorin (ezetimibe/simvastatin) vs simvastatin (Study P04103AM3). http://clinicaltrials.gov/show/NCT00202878. Accessed June 9, 2009.
9. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif J-C, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
10. Berenson A. Pfizer ends studies on drug for heart disease. New York Times. New York; December 3, 2006.
11. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.
12. Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG. on Behalf of the Department of Veterans Affairs Cooperative Studies Program No.424 (COURAGE Trial) Investigators and Study Coordinators. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circulation: Cardiovasc Qual Outcomes. 2008;1:12-20.
13. Califf RM. Angiographic profiles in courage. Circulation: Cardiovasc Qual Outcomes. 2009;2:292-293.
14. Mancini GBJ, Bates ER, Maron DJ, Hartigan P, Dada M, Gosselin G, Kostuk W, Sedlis SP, Shaw LJ, Berman DS, Berger PB, Spertus JA, Mavromatis K, Knudtson M, Chaitman BR, O'Rourke RA, Weintraub WS, Teo K, Boden WE; on behalf of the COURAGE Trial Investigators and Coordinators. Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE Trial. Circulation: Cardiovasc Qual Outcomes. 2009;2:320-327.
15. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ, Henderson WG. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med. 351: 2795-2804.
16. Eagle KA, Gurm HS. We were fishing for TROUT and we caught a CARP. Circulation: Cardiovasc Qual Outcomes. 2009;2:61-62.
17. Garcia S, Moritz TE, Goldman S, Littooy F, Pierpont G, Larsen GC, Reda DJ, Ward HB, McFalls EO. Perioperative complications after vascular surgery are predicted by the revised cardiac risk index but are not reduced in high-risk subsets with preoperative revascularization. Circulation: Cardiovasc Qual Outcomes. 2009;2:73-77.